Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.105 USD | +0.72% | +1.44% | -29.43% |
May. 07 | Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell | MT |
May. 07 | Top Premarket Gainers | MT |
Financials (USD)
Sales 2024 * | 323M | Sales 2025 * | 417M | Capitalization | 396M |
---|---|---|---|---|---|
Net income 2024 * | -10M | Net income 2025 * | 46M | EV / Sales 2024 * | 0.53 x |
Net cash position 2024 * | 223M | Net cash position 2025 * | 342M | EV / Sales 2025 * | 0.13 x |
P/E ratio 2024 * |
-35.6
x | P/E ratio 2025 * |
11.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.48% |
Latest transcript on Esperion Therapeutics, Inc.
1 day | +2.15% | ||
1 week | +1.46% | ||
Current month | +6.09% | ||
1 month | -25.09% | ||
3 months | -18.99% | ||
6 months | +136.43% | ||
Current year | -30.10% |
Managers | Title | Age | Since |
---|---|---|---|
Sheldon Koenig
CEO | Chief Executive Officer | 58 | 20-12-14 |
Director of Finance/CFO | 38 | 19-12-31 | |
JoAnne Foody
CTO | Chief Tech/Sci/R&D Officer | 59 | 21-06-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 52 | 22-04-27 | |
J. Carroll
CHM | Chairman | 74 | 22-05-31 |
Alan Fuhrman
BRD | Director/Board Member | 67 | 20-03-15 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | +2.89% | - | |
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 2.105 | +0.72% | 5 531 716 |
24-05-09 | 2.09 | +2.45% | 7,469,605 |
24-05-08 | 2.04 | -13.92% | 13,971,539 |
24-05-07 | 2.37 | +11.79% | 45,902,476 |
24-05-06 | 2.12 | +1.92% | 6,816,851 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.10% | 396M | |
+32.36% | 695B | |
+26.51% | 568B | |
-4.40% | 361B | |
+19.46% | 330B | |
+3.50% | 283B | |
+16.87% | 239B | |
+8.06% | 204B | |
-7.48% | 198B | |
+8.62% | 168B |
- Stock Market
- Equities
- ESPR Stock